The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital mortality
Synolaki et al.,
The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently associated with in-hospital..,
medRxiv, doi:10.1101/2020.09.05.20184655 (Preprint)
Retrospective 117 patients, 58 HCQ showing lower mortality for HCQ patients.
Version 1 of this paper stated: "HCQ, AZ, [and ...] were found to be independently associated with survival when treatment commenced at FACTCLINYCoD scores <3".
Although the 24% lower mortality is not statistically significant, it is consistent with the significant 22% lower mortality
[18‑27%] from meta analysis of the
232 mortality results to date.
risk of death, 23.6% lower, RR 0.76, p = 0.27, treatment 21 of 98 (21.4%), control 60 of 214 (28.0%), NNT 15.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Synolaki et al., 5 Sep 2020, retrospective, Greece, preprint, 20 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.09.05.20184655; this version posted October 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Running head: Activin/Follistatin-axis in COVID-19
The Activin/Follistatin-axis is severely deregulated in COVID-19 and independently
associated with in-hospital mortality
Evgenia Synolaki1, Vasileios Papadopoulos2*, Georgios Divolis1*, Olga Tsahouridou3,
Efstratios Gavriilidis2, Georgia Loli3, Ariana Gavriil1, Christina Tsigalou4, Nikolaos R.
Tziolos5, Eleni Sertaridou6, Bhanu Kalra7, Ajay Kumar7, Petros Rafailidis8, Arja
Pasternack9, Dimitrios T. Boumpas5, Georgios Germanidis3, Olli Ritvos9, Simeon
Metallidis3, Panagiotis Skendros2,10,# and Paschalis Sideras1,#
1
Biomedical Research Foundation Academy of Athens, Center for Clinical,
Experimental Surgery & Translational Research, Athens, Greece; 2First Department of
Internal Medicine, University Hospital of Alexandroupolis, Democritus University of
Thrace, Alexandroupolis, Greece; 3First Department of Internal Medicine, AHEPA
University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;
4
Laboratory of Microbiology, University Hospital of Alexandroupolis, Democritus
University of Thrace, Alexandroupolis, Greece; 5Fourth Department of Internal
Medicine, Attikon University Hospital, National and Kapodistrian University of
Athens Medical School, Athens, Greece; 6Intensive Care Unit, University Hospital of
Alexandroupolis, Alexandroupolis, Greece; 7AnshLabs, Webster, Texas, USA; 8Second
Department of Internal Medicine, University Hospital of Alexandroupolis,
Democritus University of Thrace, Alexandroupolis, Greece;
9
Department of
Physiology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 10Laboratory
of Molecular Hematology, Democritus University of Thrace, Alexandroupolis, Greece;
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.09.05.20184655; this version posted October 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
*
These authors contributed equally to the study.
#
These authors supervised equally the study.
Corresponding author: Dr. Paschalis Sideras; Biomedical Research Foundation
Academy of Athens, Center for Clinical, Experimental Surgery & Translational
Research, Athens, Greece; tel: +302106597183; e-mail: sideras@bioacademy.gr
2
medRxiv preprint doi: https://doi.org/10.1101/2020.09.05.20184655; this version posted October 27, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Potential conflicts of interest: Authors BK and AK are employees of Ansh Labs, which
is the manufacturer of the ELISA kits used in this study. The rest of the authors
declare no conflict of interest.
Funding Support: This work was supported by grants from the General..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit